Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;19(11):1805-1824.
doi: 10.2174/1570159X19666210211150856.

Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications

Yusuf Cem Kaplan  1 , Omer Demir  2
Affiliations
Review

Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications

Yusuf Cem Kaplan et al. Curr Neuropharmacol. 2021.

Abstract

It is challenging to balance the fetal risks associated with the use of antiepileptic drugs (AEDs) against maternal and fetal risks of seizure worsening, and therefore it is very important to define and distinguish the possible risks entailed by different AEDs. This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital, and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy. The review focuses on major and organ-specific malformations, dose-dependent risks, mono vs polytherapy, and clinical pharmacokinetics. A discussion regarding the safety of AED use during breastfeeding is also provided.

Keywords: Pregnancy; antiepileptics; breastfeeding; carbamazepine; lamotrigine; levetiracetam.; major malformations; phenobarbital; phenytoin; valproate.

PubMed Disclaimer

References

    1. Tomson T., Battino D., Craig J., Hernandez-Diaz S., Holmes L.B., Lindhout D., Morrow J., French J., Strategies I.C.T. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia. 2010;51(5):909–915. doi: 10.1111/j.1528-1167.2010.02525.x. - DOI - PubMed
    1. Scheuerle A.E., Holmes L.B., Albano J.D., Badalamenti V., Battino D., Covington D., Harden C., Miller D., Montouris G.D., Pantaleoni C., Thorp J., Tofighy A., Tomson T., Golembesky A.K. Levetiracetam pregnancy registry: Final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations. Birth Defects Res. 2019;111(13):872–887. doi: 10.1002/bdr2.1526. - DOI - PubMed
    1. Brent R.L. Saving lives and changing family histories: appropriate counseling of pregnant women and men and women of reproductive age, concerning the risk of diagnostic radiation exposures during and before pregnancy. Am. J. Obstet. Gynecol. 2009;200(1):4–24. doi: 10.1016/j.ajog.2008.06.032. - DOI - PubMed
    1. Nava-Ocampo A.A., Koren G. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach. Clin. Obstet. Gynecol. 2007;50(1):123–131. doi: 10.1097/GRF.0b013e31802f1880. - DOI - PubMed
    1. Correa A., Cragan J.D., Kucik J.E., Alverson C.J., Gilboa S.M., Balakrishnan R., Strickland M.J., Duke C.W., O’Leary L.A., Riehle-Colarusso T., Siffel C., Gambrell D., Thompson D., Atkinson M., Chitra J. Reporting birth defects surveillance data 1968-2003. Birth Defects Res. A Clin. Mol. Teratol. 2007;79(2):65–186. - PubMed